RVL Pharmaceuticals PLC
OTC:RVLPQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
RVL Pharmaceuticals PLC
Accumulated Depreciation
RVL Pharmaceuticals PLC
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
RVL Pharmaceuticals PLC
OTC:RVLPQ
|
Accumulated Depreciation
-$1.2m
|
CAGR 3-Years
56%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accumulated Depreciation
-$31.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accumulated Depreciation
-$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accumulated Depreciation
-$17.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accumulated Depreciation
-$21.9B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accumulated Depreciation
-$12.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-4%
|
|
RVL Pharmaceuticals PLC
Glance View
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 156 full-time employees. The company went IPO on 2018-10-12. The firm is focused on developing and commercializing eyecare and medical aesthetics products. The firm is engaged in the development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The firm delivers Upneeq (oxymetazoline hydrocholoride ophthalmic solution, 0.1%) for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the non-surgical treatment option for acquired blepharoptosis.
See Also
What is RVL Pharmaceuticals PLC's Accumulated Depreciation?
Accumulated Depreciation
-1.2m
USD
Based on the financial report for Dec 31, 2022, RVL Pharmaceuticals PLC's Accumulated Depreciation amounts to -1.2m USD.
What is RVL Pharmaceuticals PLC's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
27%
Over the last year, the Accumulated Depreciation growth was 25%. The average annual Accumulated Depreciation growth rates for RVL Pharmaceuticals PLC have been 56% over the past three years , 27% over the past five years .
